Design, Synthesis, Biological Activity and Molecular Docking Study of Coumarin Derivatives Bearing 2-Methylbiphenyl Moiety

Abstract

A hybrid pharmacophore approach was used to design and synthesize a series of coumarin derivatives bearing 2-methylbiphenyl moiety, which were evaluated for their in vitro anticancer activities against four cancer cell lines(MCF-7, A549, H460 and HT29) and PD-1/PD-L1 inhibitory activities. Moreover, several compounds with excellent anticancer activities were selected to evaluate the cytotoxicities against one normal cell line(HEK-293). The most promising compound 11o showed the best anticancer activities against the four tested cancer cell lines with the IC₅₀ values of 6.45, 8.65, 6,57 and 8.13 μmol/L, respectively, and displayed weak cytotoxicity on the normal cell(HEK-293). Furthermore, screening of PD-1/PD-L1inhibitory activity revealed that compound 11o could effectively inhibit the binding of PD-1/PD-L1, and the binding interactions of compound 11o with PD-L1 protein were explored by molecular docking. All above evidences showed that compound 11o might be worthy of further study as a valuable leading compound for the treatment of cancer.

Keywords

Coumarin / 2-Methylbiphenyl / Anticancer activity / PD-1/PD-L1 inhibitory activity / Molecular docking

References

[1] Kim S. K., Kalimuthu S. Handbook of Anticancer Drugs from Marine Origin, 2015

[2] Hu Y., Shen Y., Wu X., Tu X., Wang G. X. Eur. J. Med. Chem., 2018, 143: 958.

[3] Weigt S., Huebler N., Strecker R., Braunbeck T., Broschard T. H. Reprod. Toxicol., 2012, 33(2): 133.

[4] Pérez-Cruz K., Moncada-Basualto M., Morales-Valenzuela J., Barriga-González G., Navarrete-Encina P., Núñez-Vergara L., Squella J. A., Olea-Azar C. Arab. J. Chem., 2018, 11(4): 525.

[5] Keri R. S., Sasidhar B. S., Nagaraja B. M., Santos M. A. Eur. J. Med. Chem., 2015, 100: 257.

[6] Koparde S., Hosamani K. M., Kulkarni V., Joshi S. D. Chem. Dat. Collect., 2018, 15/16: 197.

[7] Ghanei-Nasab S., Khoobi M., Hadizadeh F., Marjani A., Moradi A., Nadri H., Emami S., Foroumadi A., Shafiee A. Eur. J. Med. Chem., 2016, 121: 40.

[8] Shen Y. F., Liu L., Feng C. Z., Hu Y., Chen C., Wang G. X., Zhu B. Fish Shellfish Immunol., 2018, 81: 57.

[9] Escudero G. E., Laino C. H., Echeverría G. A., Piro O. E., Martini N., Rodríguez A. N., Martínez M. J. J., López T. L. L., Ferrer E. G., Williams P. A. M. Chem. Biol. Interact., 2016, 249: 46.

[10] Woo L. W. L., Ganeshapillai D., Thomas M. P., Sutcliffe O. B., Malini B., Mahon M. F., Purohit A., Potter B. V. L. ChemMedChem, 2011, 6(11): 2019.

[11] Stefanachi A., Favia A. D., Nicolotti O., Leonetti F., Pisani L., Catto M., Zimmer C., Hartmann R. W., Carotti A. J. Med. Chem., 2011, 54(6): 1613.

[12] Reddy N. S., Gumireddy K., Mallireddigari M. R., Cosenza S. C., Venkatapuram P., Bell S. C., Reddy E. P., Reddy M. V. R. Biorg. Med. Chem., 2005, 13(9): 3141.

[13] Kusuma B. R., Khandelwal A., Gu W., Brown D., Liu W., Vielhauer G., Holzbeierlein J., Blagg B. S. J. Biorg. Med. Chem., 2014, 22(4): 1441.

[14] Wu X. Q., Huang C., Jia Y. M., Song B. A., Li J., Liu X. H. Eu.r. J. Med. Chem., 2014, 74: 717.

[15] Guzik K., Zak K. M., Grudnik P., Magiera K., Musielak B., Törner R., Skalniak L., Dömling A., Dubin G., Holak T. A. J. Med. Chem., 2017, 60(13): 5857.

[16] Zak K. M., Grudnik P., Guzik K., Zieba B. J., Musielak B., Dömling A., Dubin G., Holak T. A. Oncotarget, 2016, 7(21): 30323.

[17] Chupak L. S., Zhang X. F. Compounds Useful as Immunomodulators, 2015.

[18] Pan S., Wu X., Jiang J., Gao W., Wan Y., Cheng D., Han D., Liu J., Englund N. P., Wang Y., Peukert S., Miller-Moslin K., Yuan J., Guo R., Matsumoto M., Vattay A., Jiang Y., Tsao J., Sun F., Pferdekamper A. C., Dodd S., Tuntland T., Maniara W., Kelleher J. F., Yao Y. M., Warmuth M., Williams J., Dorsch M. ACS Medicinal Chemistry Letter, 2010, 1(3): 130.

[19] Tauchi T. Ar.thrit. Res. Ther., 2012, 14(1): O43.

[20] Fendrich V., Wiese D., Waldmann J., Lauth M., Heverhagen A. E., Rehm J., Bartsch D. K. Ann. Surg., 2011, 254(5): 818.